Healthcare Industry News:  coated stent 

Devices Interventional Cardiology Litigation

 News Release - January 4, 2007

French Court Rules in Favor of evYsio Medical Devices in Patent Litigation Against Abbott Laboratories

Xience(TM) V Drug-coated stent Now Under Injunction in France

VANCOUVER, British Columbia--(HSMN NewsFeed)--evYsio Medical Devices ULC, a private Canadian company, announced that a French court has ruled in its favor in a patent infringement lawsuit it commenced against affiliates of Abbott Laboratories (NYSE:ABT ). In particular, the Tribunal de Grande Instance de Paris ruled that Abbott's Xience(TM) V drug-eluting coronary stent infringes evYsio's European Patent No. EP-B- 0 888 093 and has awarded evYsio the right to enjoin the importation, offering for sale, or sale of the Xience(TM) V stent in France. This injunction is now in effect. Abbott may appeal the decision.

evYsio and/or Medtronic, Inc. (NYSE:MDT ) have commenced infringement lawsuits in other countries alleging that Abbott's MULTI-LINK Vision® and/or Xience(TM) V coronary stents infringe patents under exclusive worldwide license to Medtronic from evYsio, including in the United States, Ireland, the United Kingdom, and Germany.

Background on evYsio

evYsio Medical Devices ULC is a private, Vancouver-based developer of vascular medical products. It develops lesion-specific stents and special medical devices for use in the fields of interventional cardiology, radiology and endovascular medicine.


Source: evYsio Medical Devices

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.